77P A new prognostic index for patients with advanced BTC treated with cisplatin, gemcitabine and durvalumab
M. Persano(University of Cagliari), A. Casadei Gardini(IRCCS Ospedale San Raffaele), Stefano Tamberi(Azienda Unità Sanitaria Locale Della Romagna), Oluseyi Abidoye(Mayo Clinic), Gaia Giordano(University of Foggia), Fabian Finkelmeier(Goethe University Frankfurt), Lorenzo Fornaro(Azienda Ospedaliera Universitaria Pisana), Ilario Giovanni Rapposelli(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Silvia Lonardi(University of Brescia), Stephen L. Chan(Chinese University of Hong Kong), J.W. Kim(Seoul National University Bundang Hospital), M. Scartozzi(University of Cagliari), L. Rimassa(IRCCS Humanitas Research Hospital), Jessica Lucchetti(Campus Bio Medico University Hospital), Hanne Vandeputte(KU Leuven), Chi‐Hyeon Yoo(Asan Medical Center), Hong Jae Chon(CHA University Bundang Medical Center), Tatsunari SATAKE(National Cancer Center Hospital East), F. Nicchetti(Fondazione IRCCS Istituto Nazionale dei Tumori), Lorenzo Antonuzzo(Azienda Ospedaliero-Universitaria Careggi)
Cited by 0
Related Papers
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k